Sort
48,018 grants matching “immunotherapy”
Brain targeted nanoparticle for Alzheimer's disease therapy
$366,250Peisheng Xu · University Of South Carolina At Columbia · R01 · FY2020 · AG
Tailoring AAV Vectors for Glioma Immunotherapy
$366,250Ou Cao · University Of Florida · R01 · FY2008 · AI
Brain targeted nanoparticle for Alzheimer's disease therapy
$366,250Peisheng Xu · University Of South Carolina At Columbia · R01 · FY2017 · AG
The Pancreatic Cancer Microenvironment
$366,246Rui Kang · Ut Southwestern Medical Center · R01 · FY2023 · CA
Project 2: Androgen deprivation as an immune modulating therapy in combination with targeted immunotherapy of prostate cancer
$366,237Douglas G McNeel · University Of Wisconsin-Madison · P50 · FY2025 · CA
CD8 T Cell Replicative Senescence & HIV Disease
$366,235Rita Brickman Effros · University Of California Los Angeles · R01 · FY2007 · AI
Ricin-Mechanism, Transition State and Inhibitor Design
$366,196Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2011 · CA
TREATMENT OF AUTOIMMUNITY WITH RECEPTOR-MODIFIED T CELLS
$366,188Terrence L Geiger · St. Jude Children'S Research Hospital · R01 · FY2006 · AI
Identifying, Characterizing, and Targeting Regulators of B Cell Activation
$366,186Katherine Julia Susa · University Of California, San Francisco · DP5 · FY2023 · OD
CLINICAL TRIALS OF ALLOGENEIC STEM CELL TRANSPLANT IN LYMPHOHEMATOPOIETIC DISORDE
$366,186Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2011 · CA
Mitochondrial stress promotes immunosuppressive potential of myeloid subsets in tumors
$366,172Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2024 · CA
Quantitatively modeling immune responses to cancer
$366,151Matthew Spitzer · University Of California, San Francisco · DP5 · FY2020 · OD
Formulation to Generate Tolerance Towards Type 1 Diabetes
$366,138Kristy M Ainslie · Univ Of North Carolina Chapel Hill · R01 · FY2024 · DK
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevices
$366,134Oliver Jonas · Brigham And Women'S Hospital · R01 · FY2018 · CA
New Peptides for the Treatment of Multiple Sclerosis
$366,133Christine Beeton · Baylor College Of Medicine · R01 · FY2012 · NS
Mutant BRAF as a Therapeutic Target for Melanoma
$366,128Dorothee M Herlyn · Wistar Institute · P01 · FY2012 · CA
(PQ11) Targeting STING in the context of chemoradiation therapy to overcome poor preexisting immunity in mouse models of pancreatic cancer.
$366,114Marka Crittenden · Providence Portland Medical Center · R01 · FY2019 · CA
Bacterial and Liposomal Antigen Processing
$366,089Case Western Reserve University · R01 · FY2005 · AI
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$366,076David E Fisher · Massachusetts General Hospital · R01 · FY2022 · CA
PATHOGENESIS OF C NEOFORMANS PERSISTENCE
$366,075Yeshiva University · R01 · FY2000 · HL
Novel Nanotechnologies and Molecular Imaging Approaches for Cancer Immunotherapy
$366,024Caius Gabriel Radu · California Institute Of Technology · U54 · FY2011 · CA
Role of B-cell mediated anti-tumor antibodies in responses to radiation and immunotherapy in HNSCC
$366,015Andrew B. Sharabi · University Of California, San Diego · R01 · FY2019 · DE
Genome-wide mapping and characterization of exitrons in human cancer
$366,003Rendong Yang · Northwestern University At Chicago · R01 · FY2022 · CA
Tumor-associated neutrophils in human lung cancer
$366,000Evgeniy Eruslanov · University Of Pennsylvania · R01 · FY2016 · CA
Off-the-shelf engineered NK cells for the treatment of AML
$366,000Katy Rezvani · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA